Table 3

Description of studies included in the cost review

Study	Location	Study design	Impact of pharmacy access
Marciante et al 2001100	USA	Decision model	Among private payers (private insurance): US$158 (95% CI=US$76 to US$269) reduction in cost per woman having unprotected intercourse. Among public payers: US$48 (95% CI=US$16 to US$93) reduction in cost per woman having unprotected intercourse.
Soon et al 2007101	Canada	Three decision models	One-year cost saving to the MOH of US$0.64 million (95% CI: US$0.24 million to US$1.28 million). In sensitivity analyses, there were no set of assumptions that would lead to pharmacy access increasing costs to the MOH.
Foster et al 201099	USA	Markov model	For Medicare: compared with no ECP use, pharmacy access was more cost-effective than prescription access across all assumptions of amount and frequency of use. Cost savings ratios for pharmacy access: range 1.61–2.49. For prescription-only access: range 1.00–1.56.